The MIT Technology Review (also known as the MIT Technology Review) recently released the list of "Top 50 Innovative Companies" in 2016. As one of the "MIT Technology Review" annual awards, the industry often uses "the world's smartest". The company to describe the list.
What are the requirements for achieving the “most intelligent†of the MIT selection? MIT has said that companies entering the list must have truly innovative technology and a business model that is both practical and ambitious. It is observed that MIT's "smart" standards are innovations in the field of technology and exploration of new business models, with little to do with reputation and market capitalization.
In their view, if every breakthrough in the technology field is likely to cause profound changes in society, smart companies will invest more time and money into research and development to occupy emerging markets earlier. The first person to eat crabs always masters the market initiative and absolute market share.
The so-called "smart" is also the vision of a company.
Last year, Tesla, Xiaomi, Illumina, Alibaba, Tencent, Google, Amazon, Apple, and Baidu were all on the list. However, the First Financial Reporter found that in this year's list, compared with the booming technology companies in the past, this year's " health , health" companies can be described as unique, reaching 14, which is close to one-third of the total. There are as many as 10 companies involved in the genetic field.
In terms of rankings, Amazon, Illumina ( gene sequencing company), Baidu ranked in the top three.
Let's take a look at who are the 14 smartest health care companies?
1. Illunima:
The company was formed in 1998 and was completed in 2000. As the world's largest sequencing company, Illumina is expanding its reach into the downstream healthcare sector. On January 10 this year, Illumina announced the formation of blood genetic testing company Grail, which attempts to detect early cancers without clinical manifestations by deep sequencing of DNA fragments in the blood. And the price will not exceed $1,000. This will greatly reduce the threat of cancer to human life. Illumina teamed up with Microsoft founder Bill Gates and Amazon founder Jeff Bezos to inject $1 million in Series A investment into Grail.
Company valuation: 20 billion US dollars
2, 23andMe
23andMe is a leading global personal genetic testing company. Founded in 2006 by Linda Avey, Paul Cusenza and Anne Wojcicki, the company was founded to help people acquire and understand their genetic information and hope they can benefit from it.
Regarding the development history of 23andMe, the practitioners in the genetic testing industry should have studied thoroughly, and even become familiar with it. After receiving a $115 million E round in October 2015, 23andMe received more than $300 million in financing.
23andMe also cooperates with pharmaceutical giants including Genentech and Pfizer. Last year, 23andMe even announced that he had set up a medical team and that the heart of the medical field was clear.
After a long and arduous circumstance with the FDA, the first direct-to-consumer genetic test on February 19, 2015 was finally approved by the FDA. In October of the same year, 23andMe announced that there are more than 60 health, traits, and ancestral-related genetic analyses that meet the standards set by the FDA and can be targeted to consumers.
Company valuation: $1.1 billion
3, Spark Therapeutics
Founded in October 2013, Spark Therapeutics is a biotechnology innovation company dedicated to genetic diseases. Focus on hereditary retinal dystrophy, blood system diseases and neurodegenerative diseases. Spark's entrepreneurial team has been conducting research on the technology platform at Philadelphia Children's Hospital for 20 years. At the end of last year, Spark announced that its clinical trial of the eye disease gene therapy drug SPK-RPE65 has achieved very good results. Now Spark has become a leader in gene therapy.
Company valuation: $918 million
4, Cellectis
Cellectis was founded in 1999 and was first publicly offered in Europe in 2007, but the market response was not strong. Until it combined CAR-T with TALEN gene editing technology, it was optimistic about capital. In March 2015, Cellectis was in Nass. Dak launched the IPO and successfully seized $228 million. The financing amount is second only to the genetic editing giant Juno.
In November 2015, Cellectis' CAR-T cell strain successfully saved the life of Layla, a 1-year-old girl suffering from leukemia, and the world shook. The reason why it attracts great attention from society is because Cellectis' CAR-T cell strain is different from traditional CAR-T therapy. Cellectis uses the TALEN gene editing technology to "close" genes that cause human rejection. The CAR-T is made into UCART (Universal Chimeric Antigene Receptor T-cells). The benefits of UCART therapy are obvious. Because this CAR-T rejection-related gene is turned off, it can theoretically be imported into all patients without the need for matching. As long as it encounters similar diseases, UCART can For the treatment of all patients.
Compared with the traditional CAR-T's treatment fee of about 400,000 US dollars, and the difficulty of standardization caused by extreme personalization; UCART tens of thousands of dollars in treatment costs, a UCART package to play a broad spectrum of diseases, making the innovator Cellectis It has a huge advantage in the CAR-T field.
Company valuation: $1 billion
Product type: Special for milk tea, coffee, ice cream, cereal, baking, seasoning, soup, etc.
Applications: milk drinks, vegetable protein drink,coffee, seasoning,solid beverage, soft beverage,baked goods, confectionery, chocolate,jelly,ice cream and so on.
Non dairy cream also known as vegetable fat powder, Milk Replacer, coffee whitener.
Non Dairy Creamer,Vegan Non Dairy,Filled Fat Milk Powder,Non Dairy Coffee Creamer
KARAK , https://www.jskarak.com